مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

تقرير يلقي الضوء على تأثير الأزمة السورية على المستشفيات الحكومية


The impact of the Syrian crisis on Lebanon has been profound particularly in the healthcare sector. The influx of Syrian refugees has strained the public hospitals and their ability to respond to the crisis, resulting in:
  • An increased demand for healthcare services;
  • An increase in unpaid health services to refugees;
  • A sharp rise in communicable diseases and emergence of new diseases in Lebanon;
  • Increased risks of epidemics such as water-borne diseases, measles, and tuberculosis 1.
Neither United Nations High Commissioner of Refugees (UNHCR) nor other Non-Governmental Organizations (NGO) was able to meet the required level of funding to provide refugees with an acceptable level of secondary and tertiary healthcare services. They, therefore, decided to change their model of response in terms of healthcare support to Syrian refugees. As of 2014, UNHCR started covering 75% instead 85% of the hospitalization cost, leaving the patient with the remaining share of 25% to be paid out of pocket or by a third party. The healthcare referrals covered by UNHCR are limited to deliveries and life-threatening emergencies 2.

Hospitals are overburdened with Syrian patients who are unable to pay their part of the bill (increased to 25% of their total hospital fees) as well as patients whose hospitalizations are not subsidized at all. Some hospitals have put in place strategies to recover as much of the 25% as possible (deposits, retaining IDs/corpses, inflating bills). Referral of uncovered Syrian patients with complicated morbidities to public hospitals has become a common practice by private hospitals.

Overwhelmed by the high demand of healthcare by Syrian refugees, public hospitals end up treating patients without any specific reimbursement scheme thus creating a huge financial burden. This burden adds up to the existing difficult financial situation of public hospitals, putting the whole healthcare sector under stress. Public hospitals are restrained from completing their mission and incapable of providing healthcare services neither to Syrians refugees nor to Lebanese citizens...
    ...
    110
    ...
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
A10BD15 DIAFLOZIN PLUS G Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet, film coated 2,483,421 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 5mg Tablet 3,867,041 L.L
A10BD15 DIAFLOZIN PLUS G Metformin HCl XR - 1000mg, Dapagliflozin - 5mg Tablet, film coated 1,241,710 L.L
A10BD02 DIAMET 500/5 G Metformin HCl XR - 500mg, Glibenclamide - 5mg Tablet, film coated 639,925 L.L
H03BB02 THYROZOL B Methimazole (Thiamazole) - 10mg 10mg Tablet, film coated 326,554 L.L
H03BB02 TAPAZOLE B Methimazole (Thiamazole) - 5mg 5mg Tablet 565,694 L.L
H03BB02 THYROZOL B Methimazole (Thiamazole) - 5mg 5mg Tablet, film coated 233,829 L.L
M03BA03 LUMIRELAX B Methocarbamol - 500mg 500mg Tablet 667,890 L.L
M03BA03 METOFLEX G Methocarbamol - 750mg 750mg Tablet 2,941,671 L.L
L04AX03 EBETREXAT G Methotrexate - 15mg/1.5ml 15mg/1.5ml Injectable solution 2,135,366 L.L
L01BA01 METHOTREXAT EBEWE G Methotrexate - 500mg 500mg Injectable solution 1,842,408 L.L
L01BA01 EBETREXAT G Methotrexate - 50mg/5ml 50mg/5ml Injectable solution 1,507,821 L.L
L04AX03 EBETREXAT G Methotrexate - 5mg 5mg Tablet, scored 2,488,796 L.L
L04AX03 METOJECT G Methotrexate disodium - 10mg/0.2ml 10mg/0.2ml Injectable solution 1,553,482 L.L
L04AX03 METOJECT G Methotrexate disodium - 15mg/0.3ml 15mg/0.3ml Injectable solution 1,968,729 L.L
L04AX03 METOJECT G Methotrexate disodium - 20mg/0.4ml 20mg/0.4ml Injectable solution 2,134,022 L.L
L04AX03 METOJECT G Methotrexate disodium - 25mg/0.5ml 25mg/0.5ml Injectable solution 2,582,865 L.L
N02BG09 PENTHROX INHALER B Methoxyflurane - Inhalation 21,080,096 L.L
C02AB02 ALDOMET B Methyldopa - 250mg 250mg Tablet, coated 644,400 L.L
C02AB02 ALDOMET B Methyldopa - 500mg 500mg Tablet, coated 856,708 L.L
N06BA04 RITALIN B Methylphenidate HCl - 10mg 10mg Tablet 376,276 L.L
N06BA04 CONCERTA B Methylphenidate HCl - 18mg 18mg Tablet, extended release 3,133,841 L.L
N06BA04 CONCERTA B Methylphenidate HCl - 27mg 27mg Tablet, extended release 4,393,021 L.L
N06BA04 CONCERTA B Methylphenidate HCl - 36mg 36mg Tablet, extended release 4,393,021 L.L
N06BA04 CONCERTA B Methylphenidate HCl - 54mg 54mg Tablet, extended release 6,049,979 L.L
H02AB04 METHYL PREDNISOLONE VIATRIS 120MG G Methylprednisolone (hemisuccinate) - 120mg 120mg Injectable dry powder for solution 602,536 L.L
H02AB04 METHYL PREDNISOLONE VIATRIS 1G G Methylprednisolone (hemisuccinate) - 1g 1g Injectable dry powder for solution 1,348,604 L.L
H02AB04 METHYL PREDNISOLONE VIATRIS 40MG G Methylprednisolone (hemisuccinate) - 40mg 40mg Injectable dry powder for solution 258,657 L.L
H02AB04 MP 40 G Methylprednisolone - 40mg 40mg Injectable powder for solution 219,046 L.L
    ...
    110
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025